- Series: RRMM
- Expires: May 30, 2024
- Credit: 1.00hr(s)
- AAPA, CME, CPE, IPCE, NCPD
- Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
- Specialties: CAR T-Cell Therapy, Multiple Myeloma
Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC) with actionable genetic alterations. However, the constantly changing treatment landscape plus the rapidly evolving clinical evidence and guidelines present challenges for busy oncology nursing teams. Tune into the third episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care to learn from about new and emerging targeted therapies for NSCLC and best practices for managing patients with acquired resistance.